119 filings
8-K
CARA
Cara Therapeutics Inc
18 Jun 24
Cost Associated with Exit or Disposal Activities
4:16pm
8-K
CARA
Cara Therapeutics Inc
12 Jun 24
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
5:12pm
8-K
CARA
Cara Therapeutics Inc
7 Jun 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
CARA
Cara Therapeutics Inc
13 May 24
Cara Therapeutics Reports First Quarter 2024 Financial Results
4:10pm
8-K
CARA
Cara Therapeutics Inc
22 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
4qx9fg6nhq
4 Mar 24
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
8-K
eat02ecnn
2 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:59pm
8-K
isyu7g 4s2ciwv
22 Jan 24
Cost Associated with Exit or Disposal Activities
4:19pm
8-K
tv2oj7om5m 6kaxzm3v
18 Dec 23
Regulation FD Disclosure
7:10am
8-K
gzb2co6 wtdun5lme6j
13 Nov 23
Corporate Presentation November 2023
4:28pm
8-K
stheo63833vixch aq
13 Nov 23
Cara Therapeutics Reports Third Quarter 2023 Financial Results
4:11pm
8-K
299n0j93hgul43817655
2 Nov 23
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
7:10am
8-K
09eh 1ww1nlw6cu
7 Aug 23
Corporate Presentation August 2023
4:24pm
8-K
zvywy3
7 Aug 23
Cara Therapeutics Reports Second Quarter 2023 Financial Results
4:10pm
8-K
ab0a5ih6z1n0zw4xd
3 Aug 23
Cara Therapeutics Appoints Helen M. Boudreau to
7:06am
8-K
pyzapnl7gmisordypzrl
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
5hped16ic7fmwj8eqv
15 May 23
Corporate Presentation May 2023
4:21pm
8-K
tbesiojhe24 ia28ay
15 May 23
Cara Therapeutics Reports First Quarter 2023 Financial Results
4:10pm
8-K
v2cb6adi6 fk7tj0w
23 Mar 23
Corporate Presentation March 2023
5:04pm
8-K
6nseh5g rh
10 Mar 23
Regulation FD Disclosure
5:03pm